Annals of clinical and laboratory science · 2026
Serum Progranulin as a Potential Marker for Disease Activity and Thrombotic Events in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhong Yue, Yu Wen-Lu, Lv Tie-Gang, Xu Li-Ping, Hao Jian
Аннотация
OBJECTIVE: Progranulin (PGRN) is a secreted glycoprotein that can have pro-inflammatory or anti-inflammatory effects, depending on the disease. The serum and urinary levels and mechanism of action of PGRN in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are unclear.
METHODS: Thirty patients with active AAV were enrolled from May 2022 to May 2024; 28 were myeloperoxidase-positive, and two were proteinase 3-positive. A healthy control cohort consisted of five male and five female volunteers. Age, gender, AAV subtype, and laboratory data were collected. Using an enzyme-linked immunosorbent assay, Whole blood and urine samples were collected for measurements of PGRN.
RESULTS: The median patient age was 69.0 years (range: 58.8-75.5); 56.7% of them were female, and 94.3% of them were MPO-ANCA-positive. Compared with healthy controls, the AAV patients had higher serum PGRN levels (52.0±30.9 vs. 3.3±1.7 ng/mL, P<0.05) and lower urinary PGRN levels. The serum PGRN level also had a positive correlation with the Birmingham vasculitis activity score (r=0.776, P<0.001), and moderate positive correlations with coagulation-related parameters (activated partial thromboplastin time, fibrin degradation products, and D-dimer). Patients who subsequently developed thrombotic events had higher serum PGRN levels than those without thrombotic events.
CONCLUSION: The serum PGRN level was associated with disease activity and coagulation abnormalities in patients with active AAV, particularly in those with MPO-ANCA positivity. Although serum PGRN had a positive association with thrombotic events, its elevation may be influenced by renal dysfunction and systemic inflammation. Therefore, serum PGRN may serve as an activity-related biomarker rather than a disease-specific marker in AAV.
METHODS: Thirty patients with active AAV were enrolled from May 2022 to May 2024; 28 were myeloperoxidase-positive, and two were proteinase 3-positive. A healthy control cohort consisted of five male and five female volunteers. Age, gender, AAV subtype, and laboratory data were collected. Using an enzyme-linked immunosorbent assay, Whole blood and urine samples were collected for measurements of PGRN.
RESULTS: The median patient age was 69.0 years (range: 58.8-75.5); 56.7% of them were female, and 94.3% of them were MPO-ANCA-positive. Compared with healthy controls, the AAV patients had higher serum PGRN levels (52.0±30.9 vs. 3.3±1.7 ng/mL, P<0.05) and lower urinary PGRN levels. The serum PGRN level also had a positive correlation with the Birmingham vasculitis activity score (r=0.776, P<0.001), and moderate positive correlations with coagulation-related parameters (activated partial thromboplastin time, fibrin degradation products, and D-dimer). Patients who subsequently developed thrombotic events had higher serum PGRN levels than those without thrombotic events.
CONCLUSION: The serum PGRN level was associated with disease activity and coagulation abnormalities in patients with active AAV, particularly in those with MPO-ANCA positivity. Although serum PGRN had a positive association with thrombotic events, its elevation may be influenced by renal dysfunction and systemic inflammation. Therefore, serum PGRN may serve as an activity-related biomarker rather than a disease-specific marker in AAV.